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ABSTRACT: Given the potent anticancer properties of cis-
diamminedichloroplatinum(II) and knowing its mode of action, we
synthesized four new cis-[PtCl2(N^N)] organoplatinum complexes, two
with N-substituted pbi ligands (pbiR = 1-R-2-(2-pyridyl)benzimidazole)
(namely, 1 and 2) and two more with 4,4′-disubstituted bpy ligands (bpy =
2,2′-bipyridine) (namely, 3 and 4). We explored their cytotoxicity and
ability to bind to deoxyguanosine monophosphate (dGMP), DNA, and
albumin models. By 1H NMR and UV−vis spectroscopies, circular
dichroism, agarose gel electrophoresis, diﬀerential scanning calorimetry
measurements, and density functional theory calculations, we veriﬁed that
only 3 can form aquacomplex species after dimethyl sulfoxide solvation;
surprisingly, 1, 2, and 3 can bind covalently to DNA, whereas 4 can form a noncovalent complex. Interestingly, only complexes 1
and 4 exhibit good cytotoxicity against human ovarian carcinoma (HeLa) cell line, whereas 2 and 3 are inactive. Although lung
carcinoma (A549) cells are more resistant to the four platinum complexes than HeLa cells, when the protein concentration in the
extracellular media is lower, the cytotoxicity becomes substantially enhanced. By native electrophoresis of bovine seroalbumin
(BSA) and inductively coupled plasma mass spectrometry uptake studies we bear out, on one hand, that 2 and 3 can interact
strongly with BSA and its cellular uptake is negligible and, on the other hand, that 1 and 4 can interact with BSA only weakly, its
cellular uptake being higher by several orders. These results point up the important role of the protein binding features on their
biological activity and cellular uptake of cis-“PtCl2” derivatives. Our results are valuable in the future rational design of new
platinum complexes with improved biological properties, as they expose the importance not only of their DNA binding abilities
but also of additional factors such as protein binding.
■ INTRODUCTION
Despite the notable advances in the discovery of new anticancer
drugs that could become alternative to cisplatin, some of the
disadvantages of this compound still remain satisfactorily
unsolved so far.1,2 It is therefore necessary to continue
designing new active structural fragments and modify those
that have proved to be ineﬀective, probably because they
present limitations to reach their target. For example, factors
such as protein binding and lipophilicity have a determinant
impact on the absorption, distribution, metabolism, and
excretion processes of the organic anticancer drugs.3
Thus, the favorable chemical formulation, size and shape, and
the judicious inclusion of functional groups to achieve a
favorable balance between lipophilicity and hydrophilicity are
essential for the correct formulation of drugs. The presence of
both lipophilic and hydrophilic groups in a drug can facilitate its
administration and cell uptake. In the design of anticancer
drugs, cellular uptake, lipophilicity, and cytotoxicity correlate in
some instances.4
[PtCl2(bpy)] (bpy = 2,2′-bipyridine) and other complexes
with bpy bisubstituted in the 4,4′ positions and rollover
cyclometalated Pt compounds based in the same backbone
exhibit lower cytotoxic activity than cisplatin.5,6 Comparable
lack of marked activity has been found for the [PtCl2(Hpbi)]
(Hpbi = 2-(2′-pyridyl)benzimidazole) counterparts.7,8 These
results are surprising if one takes into account the notable
cytotoxicity of many compounds with the cis-“PtCl2” unit, and
it might indicate the existence of limitations for these molecules
to achieve their targets. By contrast, the organometallic derivate
[PtMe(DMSO)(pbi)] (pbi = deprotonated form of Hpbi;
DMSO = dimethyl sulfoxide), also neutral, shows a notable
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activity against A2780 and A2780R cancer lines,9 indicating that
minor changes can induce pronounced diﬀerences in the
biological activity.
In this work, we propose introducing side lateral function-
alized chains in both pbi and bpy ligands, synthesizing their cis-
PtCl2 derivatives and exploring their eﬀect on the cytotoxicity
and their ability to bind to DNA and protein models. With this
in mind, the ligands and cis-PtCl2 complexes included in Chart
1 were prepared. The side chains and functional groups were
chosen considering bibliographic background in which these
substituents exert a favorable action on the eﬀect of diﬀerent
drugs. Thus, the cyano-ethyl fragment, present in complex 1,
had improved the cell permeability of drugs such as various
Janus protein tyrosine kinases (JAK) inhibitors.10 Alkyl-
sulfonate groups, like that included in complex 2, should
become deprotonated in biological media if the low pKa values
for this functional group were considered, which could favor
the solubility under physiological conditions. The biological
activity of gold and silver N-heterocyclic carbenes bearing this
group has been demonstrated both in bacteria11 and in cancer
cells.12 The propylsulfonate chain forms part of merocyanine
540. This popular probe has been used as a model to study the
permeation of cell membranes13 and is an important active
molecule, able to diﬀerentiate between the subtle diﬀerences in
the plasma membranes of very similar cells such as leukemic
and nonleukemic lymphocytes, depending on the composition
of the culture medium.14 The 5-diethylamino-2-pentylamino
group, present in 4,4′-bis(N-(4-pentyldiethylamine)-
carbamoyl)-2,2′-bipyridine (bpyam) ligand (see Chart 1) and
in complex 3, is a fragment widely used in drugs. Particularly
relevant is its role in the formulation of the antimalarial drugs,
chloroquine (CQ) and quinacrine (QC), where the stated
aminated tail is responsible for the accumulation of the drug in
the digestive vacuole of the pathogen, the site of the drug
action.15 Both of them are strong DNA intercalating agents
with cytotoxic activity16,17 that displays a synergistic eﬀect in
tumor cells treated with cisplatin.18,19 In the case of the 4,4′-
bis(α-styrene)-2,2′-bipyridine (bpyst)20,21 ligand (Chart 1) the
conjugation of the phenyl (Ph) ring and the ethylene fragment
with the bpy unit renders this ligand very attractive due to its
rigidity that enforces a plane structure.22−24 Concerning our
aims, the plane architecture makes [PtCl2(bpyst)] (complex 4)
an interesting compound to be analyzed as a potential drug
targeting DNA.
In this work, the synthesis, characterization and biological
properties of these four new organocisplatin analogues are
reported. Their binding properties to relevant biomolecules
such as DNA and serum proteins and their cellular uptake are
explored to establish which factors are determinant to their
cytotoxicity, which could, in turn, lead to future rational
structural modiﬁcations with improved biological activity.
■ RESULTS AND DISCUSSION
Synthesis and Structural Characterization. The com-
plexes prepared in this work and their respective ligands are
listed in Chart 1 along with their preparation methods. Even
though the 1-(cyanoethyl)-2-(2-pyridyl)benzimidazole
(pbiCN) ligand has been prepared previously,25 the method
described here is easier and provides a higher yield. This
method consists of the deprotonation of the NH group of the
commercially available 2-(2-pyridyl)benzimidazole and subse-
quent addition of acrylonitrile. The 1-(3-n-propylsulfonate)-2-
(2-pyridyl)benzimidazole (pbiSO3) and bpyam ligands are
reported in this work for the ﬁrst time. The pbiSO3 ligand was
prepared according to the procedure described for other n-
propylsulfonate compounds,26 by the reaction of 2-(2-pyridyl)-
Chart 1. Synthesis of Ligands and Complexes 1−4 and Atom Numbering Scheme
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benzimidazole in dimethylformamide (DMF) with 1,3-propane
sultone in the presence of K2CO3 as deprotonating salt. The
synthesis of the ligand bpyam was achieved by a classical amide
formation procedure,27 starting by the formation of the acid
chloride of the 4,4′-dicarboxy-2,2′-bipyridine and ulterior
reaction with the commercially available 5-diethylamino-2-
pentylamine. Ligand 4,4′-bis(α-styrene)-2,2′-bipyridine (bpyst)
was prepared as previously reported.28
Complexes 1−3 were prepared by the reaction of the
K2[PtCl4] salt with the respective ligands in water (3) or
acetone/water (70:30 for 1 and 50:50 for 2). While complex 3
was obtained at room temperature, the reaction to obtain 1 and
2 was performed at 50 °C. Complex 4 was obtained from the
platinum precursor [PtCl2(PhCN)2] from a 1,2-dichloroethane
solution heated at 60 °C.
All the complexes were isolated in moderate-to-good yields
(ranging from 54 to 74%) as yellow or orange-brown solids that
were air and moisture stable. All of them are soluble in DMSO
and relatively soluble in DMSO/H2O mixtures, which facilitate
the biological studies. The ligands and the complexes were
characterized by 1H, 13C{1H} NMR, and IR spectroscopies.
Fast atom bombardment (FAB) mass spectra for the complexes
were also recorded. The peaks observed are in accordance with
the proposed formulations (see Experimental Section). The
anionic complex 2 was characterized by FAB− spectrometry,
showing the corresponding peak of the anion salt. In the IR
spectra, the absorptions corresponding to the stretching
vibrations of the CN,29 SO3−,30 (CO)NH, and CC31
functional groups were observed. The assignment of the NMR
resonances was facilitated in some cases by two-dimensional
experiments such as gCOSY, NOESY, gHSQC, and gHMBC.
The NMR data with the corresponding assignments for the
new ligands and for complexes 1−4 are shown in the
Experimental Section. As expected, the coordination of the
ligands causes deshielding in the 1H NMR resonances of the
protons of the coordinated rings. The eﬀect is more marked
(∼1 ppm) in the protons adjacent to the N-donor atoms and in
H6′ of 1 and 2 and H3 of 3. It is interesting to note the splitting
of some proton (−C(O)NH, H3) or carbon (CO, C2, C4, C3,
and C4′) resonances of 3 as a consequence of the existence of
two diastereomers, due to the presence of two chiral centers in
the molecule. The weak base nature of the terminal −NEt2
groups in 3 (pKa = 12.8 in chloroquine) was evidenced in
1H
NMR spectrum in deuterated dimethyl sulfoxide (DMSO-d6),
since a very broad resonance around 9.5 ppm was present that
disappeared as D2O was added, as a consequence of deuterium
exchange (Figure S3). The presence of this resonance was
interpreted as evidence for protonation of this group by the
residual water in the DMSO-d6. As expected, the resonance
assigned to the −C(O)NH group also exchanged with D2O,
and the corresponding signal was not observed in the spectrum.
Stability in DMSO and Aqueous Solution. The
biological activity of cisplatin and its derivatives is known to
be related to substitution of the chloride ligands by other
solvent molecules such as H2O, which then leads to covalent
binding with DNA.32 As the 1−4 complexes are very soluble in
DMSO, the concentrated stock solutions (20 mM) were
prepared in this solvent, and diluted solutions in aqueous buﬀer
were then prepared prior to performing the biological
experiments. Because of this, the stability of the complexes
both in DMSO and in aqueous buﬀered solution was studied by
Figure 1. Aromatic area of 1H NMR spectra in DMSO-d6 of 2 + dGMP. (a) Complex 2 after 14 d in DMSO-d6 + D2O before addition of dGMP, (b)
free dGMP, (c) t = 0, (d) t = 30 min, (e), t = 2 h, (f) t = 3 d.
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means of NMR, spectrophotometric measurements, and/or
theoretical calculations.
Complex 1 is not soluble in DMSO/D2O mixtures at the
concentration required for the NMR experiments. Thus, the
study of the substitution of the chloride ligand by DMSO and
H2O was studied by means of UV−vis spectroscopy, which
allows working at much lower concentrations. As shown in
Figure S1, after complex 1 dissolved in DMSO (10 μM) a two-
exponential process takes place, pointing up the substitution of
the two chloride ligands by DMSO molecules with rate
constants of k1 = 0.0017 s
−1 (corresponding to formation of
[PtCl(DMSO)(pbiCN)]Cl) starting from 1 and k2 = 0.0002
s−1 (corresponding to formation of [Pt(DMSO)2(pbiCN)]-
Cl2). When water is added, the [Pt(DMSO)2(pbiCN)]Cl2
complex remains stable in solution, and no spectral changes
with time are observed. Interestingly, 1H NMR measurements
show that, despite the similar structure of complexes 1 and 2,
the second is stable in solution and undergoes no substitution
of the chloride ligands by DMSO-d6 molecules in DMSO-d6
solvent, neither by D2O (see Figure S2). The
1H NMR
spectrum of the complex 3 in DMSO-d6 shows a displacement
with time of several resonances in the aromatic region of the
spectrum, which indicates exchange of chloride ligands by one
or two solvent molecules (see Figure S3.A). When deuterated
water is added, aquation takes place, since a new complex
appeared in solution after 10 h (Figure S3.B). The signals of
complex 4 with time become broad both in DMSO-d6 (Figure
S4.A) and when deuterated water is added (Figure S4.B),
making it diﬃcult to obtain a reliable conclusion. To clarify this
issue, UV−vis spectroscopy and density functional theory
(DFT) calculations were also performed. The absorption
spectra of 4 were recorded at diﬀerent times after dissolution of
the complex in DMSO (Figure S5.A). A monoexponential
equation was ﬁtted to the absorbance−time data pairs (Figure
S5.B), indicating that the substitution occurs at least by one
chloride ligand, the rate constant being k = 0.0005 s−1. On the
contrary, no kinetic eﬀects are observed in solution when H2O
is added, indicating that aquation is absent. Indeed, DFT
calculations reveal that the substitution of not only one but also
two chloride units by DMSO molecules in 4 is thermodynami-
cally favored through SN2 substitution (Figure S6.A), whereas
the following substitution of DMSO by H2O is not favored, as
the hydrolysis product presents higher energy than the
reactants (Figure S6.B). In details, both show higher values
of the enthalpy versus the Gibbs free energy values for the
transition states involved. The three self-consistent ﬁeld (SCF)
energy, enthalpy, and Gibbs free energy values point to same
thermodynamic trend of the reaction pathway. In conclusion,
from both the UV−vis experiments and DFT calculations,
aquation for compound 4 can be discarded.
DNA Binding. As mentioned above, the biological activity
of cisplatin analogues is usually related to formulation of
covalent bonds with DNA. In particular, cisplatin is an inert
compound that is activated by a series of aquation reactions in
which one or both chloride ligands are substituted by H2O
molecules.32 These mono- and biaquated cisplatin forms are
highly reactive and prone to interact with diﬀerent substrates,
including DNA.33 Because of this, the ability of 1−4 to bind to
dGMP was ﬁrst tested by means of 1H NMR and 31P{1H}
NMR studies. After addition of dGMP to a solution of complex
2, 1H NMR spectra showed the decrease of the intensity of the
signals corresponding to free dGMP (see signal at 6.12 ppm) in
the mixture, and new signals of the complex bound to the
dGMP molecule were observed (see Figure 1). An incipient
singlet at 8.35 ppm could be assigned to H8 of dGMP due to
the binding of the platinum center to the N7 of the dGMP. The
31P{1H} spectra present a broad singlet centered at −1.5 ppm,
and no more signals were observed in the spectra after time
(see Figure S7). The nonobservation of resonances for lower
ﬁelds conveys that O-coordination of dGMP is absent or is not
signiﬁcant. In the case of complex 3, broadening of the 1H
NMR signals occurs after addition of dGMP, and an incipient
singlet can be observed at 8.16 ppm after 2 d in solution,
probably due to binding of the platinum center to N7 of dGMP
(see Figure S8). This feature reveals that the covalent binding
on 3 is rather slow compared to that of 2.
Again, 1 could not be included in the NMR studies due to its
insolubility in DMSO/D2O mixtures at the required concen-
trations. Complex 4 also precipitated after addition of dGMP
due to the relatively high concentrations needed.
To overcome this problem, circular dichroism (CD)
experiments were performed in the presence of calf-thymus
DNA (ctDNA). When complexes 1−4 were added to a ctDNA
solution, 1−3 induced slow changes with time in the CD
spectra, which stopped after 72 h, whereas the changes brought
about by complex 4 were immediate. This observation excludes
fast modes of binding like intercalation, which causes
remarkable changes in the DNA structure in the microsecond
time scale,34 for complexes 1−3. On the contrary, covalent
binding to DNA is usually slower. Actually, the ﬁrst signals
related to formation of a covalent bond between 3 and dGMP
appeared after 2 d of incubation. Thus, ctDNA was incubated
with complexes 1−4 for 72 h to properly compare their ability
to bind to DNA, thus distorting its structure in a longer time
scale under the same experimental conditions. The CD spectra
shown in Figure 2.A reveal pronounced structural changes in
the DNA molecule upon binding of complexes 1−3. As to
complex 4, as stated before, the NMR experiments with dGMP
could not be performed, and the absence of changes in the CD
spectra with time does not suﬃce to rule out covalent binding
with DNA, as platinum complexes that can form monodentate
covalent bonds do not signiﬁcantly aﬀect the CD spectra of
DNA.35 For that reason, agarose gel electrophoresis with
pUC18 plasmid incubated with diﬀerent contents of complex 4
(and also with cisplatin as a positive control for covalent
binding) was performed. As shown in Figure S9, complex 4
does not induce changes in the migration of the characteristic
plasmid DNA bands, whereas cisplatin provokes remarkable
diﬀerences. This outcome allows one to exclude the presence of
covalent binding between 4 and DNA. However, other modes
of noncovalent interaction should not be ruled out. To assess
such hypothesis, additional CD experiments were performed,
and the relative elongation (L/L0) was evaluated for diﬀerent
[complex]/[DNA] concentration (CD/CP) ratios. The CD
spectra display an isoelliptic point at 250 nm, a slight lateral
shift of the band centered at 275 nm, and a new induced CD
band at 310 nm (Figure S10.A). This behavior, along with the
changes in relative viscosity (Figure S10.B), is consistent with
formation of a noncovalent complex between 4 and DNA.
Diﬀerential scanning calorimetry (DSC) experiments were
performed to provide additional information about the binding
features of complexes 1−4 to ctDNA. Figure 2.B shows the
thermograms obtained at 25 °C for ctDNA incubated alone or
in the presence of 1−4 at 0.5 CD/CP ratio for 72 h (higher
concentration ratios could not be studied due to precipitation
phenomena). In the case of complexes 1, 2, and 3, for which
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the covalent binding to dGMP has been conﬁrmed previously
by NMR experiments, the increases in Tm were 32.5, 9.7, and
25.3 °C, respectively. On the one hand, the largest ΔTm values
are induced by 1 and 3 and could be related to formation of
interstrand cross-linking, which stabilizes the double-stranded
DNA structure.36 On the other hand, complex 4 induces a
slight increase in Tm of 4.7 °C, which could be due to the
presence of a noncovalent interaction between complex 4 and
DNA, concurrent with the CD and viscosity observations.
The results obtained for the substitution of the chloride
groups and for the covalent binding to dGMP and DNA for the
four platinum complexes as well are summarized in Table 1.
Interestingly, unlike cisplatin, clear correlation between the
chloro substitution by DMSO and H2O and the covalent
binding with DNA for complexes 1−3 seems to be absent.
Only complex 3 can form the aqua complex, and, hence, it can
bind to DNA by a similar mechanism as to cisplatin.
Cytotoxicity Studies. Once the binding ability of the four
platinum complexes with DNA was assessed, their cytotoxic
activity against human cervical carcinoma (HeLa) and human
lung carcinoma (A549) cell lines was also evaluated by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay after 72 h of incubation time. For comparison
purposes, the cytotoxicity of cisplatin was also tested. The half-
maximal inhibitory concentration (IC50) values are summarized
in Table 2. Complexes 2 and 3 are essentially nontoxic, whereas
1 is cytotoxic only toward HeLa cells. This is noteworthy,
because all three complexes have been shown to bind
covalently to DNA. As to complex 4, it can interact
noncovalently with DNA and presents intermediate cytotoxicity
toward HeLa cells. Note that 3 displays no cytotoxicity, even
though it can form the aquacomplex and interact by covalent
binding with DNA, a behavior similar to that of cisplatin; that
is, the type of the DNA interaction is not the determining
factor in the cytotoxicity of these cis-PtCl2 derivatives. This set
of results raises the question of which factors, such as cellular
uptake or protein binding, could play a key role in their
cytotoxicity.4
Many new metal complexes with novel modes of action have
been reported, and their anticancer activity was linked to
selective protein interaction that may lead to improved
accumulation in the tumor, higher selectivity, and/or enhanced
antiproliferative eﬃcacy.37 However, it was reported previously
that the binding of metal complexes to certain proteins present
in the cell culture media can aﬀect negatively their uptake due
to protein sequestration of the drug, thus aﬀecting their
biological activity.3,38 To shed some light into this issue, the
cytotoxic activity of the complexes was tested against A549 cells
in a comparative manner, using not only standard serum
supplemented (10% fetal bovine serum (FBS)) but also a
serum-deprived (1% FBS) cell culture media. FBS contains a
large amount of proteins that can interact strongly with certain
drugs, which can in turn decrease drastically their bioavail-
ability. Indeed, the cytotoxicity of complexes 1, 2, and 4
increased notably in serum-deprived media (see Table 2), in
which the protein concentration is much lower. Cisplatin is
known to interact very weakly with human serum albumin
(HSA; K = 8.52 × 102 M−1),39 which explains why its
cytotoxicity is nearly the same in the presence of 10% or 1%
FBS. Taking into account this set of results, it seems clear that
the interaction with serum albumin present in the culture
medium plays a critical role in the antiproliferative activity of
cisplatin derivatives. This behavior has been observed recently
in organic complexes3 and gold derivatives.33
Figure 2. (A) CD spectra of ctDNA (P) incubated for 72 h with
complexes 1−4 (D) at a concentration ratio CD/CP = 1 (CP = 8 × 10−5
M) at T = 25 °C, CDMSO = 0.4%. (B) DSC thermograms of ctDNA
incubated for 72 h with complexes 1−4 at a concentration ratio CD/CP
= 0.5 (CP = 4 × 10
−4 M) at a scan rate = 1 °C/min, CDMSO = 1%. I =
2.5 mM sodium cacodylate (NaCac), pH = 7.4.
Table 1. Summary of the Results of the Substitution of the
Chloride Ligands by DMSO and H2O. Covalent Binding














1 √ × n.o. √ ×
2 × × √ √ √
3 √ √ √ √ √
4 √ × n.o. × ×
a1 and 4 could not be studied due to precipitation under the 1H NMR
experimental conditions. n.o., not observed. bFor complex 4, the
interaction is only observed at high concentrations.
Table 2. Cytotoxic Activity of Complexes 1−4 and Cisplatin
Expressed as IC50 Values (μM)
IC50, μM
HeLaa A549a A549b
1 15.4 ± 0.9 >100 39.7 ± 0.7
2 >100 >100 65 ± 3
3 >100 >100 >100
4 33 ± 2 >100 41.9 ± 0.9
cisplatin 14.0 ± 0.9c 17 ± 1 14 ± 1
aSerum-supplemented media (10% FBS). bSerum-deprived media
(1% FBS). cTaken from ref 40.
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Protein Binding. Serum albumin plays a key role in drug
delivery due to its binding properties and abundance in blood
plasma. Bovine serum albumin (BSA) is a suitable model for
protein binding because of its resemblance to HSA.41
Therefore, in view of the eﬀect of the FBS concentration in
the cytotoxicity of platinum complexes, native acrylamide
electrophoresis experiments of BSA were performed to further
examine whether the protein binding could be determinant as
to their cytotoxic activity. BSA was incubated for 72 h with
complexes 1−4 in the dark at 25 °C for CD/CP concentration
ratios of 10 and 20, and then native acrylamide electrophoresis
was performed (Figure 3). Lanes 1 and 2 correspond to BSA
alone and in the presence of the maximum DMSO
concentration used in the experiment (0.3%). Noteworthy,
complexes 2 and 3, which can interact with DNA through
covalent bonding but display poor cytotoxicity, aﬀect in a deep
manner the protein conformation (lanes 5−6 and 9−10).
Complex 4 also interacts with BSA, but higher concentrations
are needed to aﬀect the BSA conformation, as there is still no
noticeable eﬀect on the protein conformation at CD/CP = 10
(lane 3). On the contrary, complex 1, the most cytotoxic, does
not aﬀect the BSA conformation even at high CD/CP ratios
(lanes 7−8).
As shown in Figure 4, circular dichroism experiments
conﬁrmed the native electrophoresis results. The incubation
of BSA with complexes 2 and 3 induced a marked change in its
characteristic λ = 220 nm negative band. Complex 4 also
modiﬁed slightly this band, whereas complex 1 had almost no
eﬀect on the shape and intensity of the protein band.
As, on one hand 1 and 2 and on the other hand 3 and 4 diﬀer
only in their tails, we can conclude that the tail plays a
determining role in their interaction with the protein. Very
recently it has been reported that chloroquine (the lateral chain
located on the backbone of complex 3) can bind to HSA.42 At
pH = 7, chloroquine (CQ) is doubly protonated in both the N
pyridine and ethylamine sites, as the resulting pKa values are 8.4
and 10.8, respectively.43 From comparison of CQ with complex
3, we can state that in aqueous solution at pH = 7 the two
ethylenamine groups are protonated (see 1H NMR in Figure
S3A). In this sense, MS-FABS+ shows that, in 15% DMSO,
complex 3 is in the [M+2H]+ form; therefore, in 0.3% DMSO
(the solvent utilized to study the interaction with BSA) the two
amines of the lateral chains will be fully protonated. Thus, the
positive charge favors the electrostatic interaction with the
negative net charge of the protein. Likewise, it was found that
negatively charged compounds bind to HSA more strongly
than expected from the lypophylicity of the ionized species at
pH 7.4,44 which is the case of complex 2. Moreover, it has been
observed that the binding of Merocyanine 540 to erythroid cells
is hindered by the presence of serum proteins in the media,14
probably due to the presence of a propylsulfonate chain in its
structure. Thus, this moiety is determining for the interaction of
complex 2 with BSA. In summary, the sets of observations
point to a key role of protein binding in the cytotoxic properties
of the platinum complexes, insofar as it could prevent the
complexes from entering the cell. The binding to BSA clearly
depends on the structure and charge of side lateral function-
alized chains, the neutral chain remaining essentially non-
interacting. For this reason, the cellular uptake of each complex
was studied by inductively coupled plasma mass spectrometry
(ICP-MS).
Cellular Uptake. The ability of the platinum complexes 1−
4 to enter the cell was also studied to compare their uptake
rates with their protein binding properties. Cells were
incubated for 24 h with 10 μM of each complex, and then
the amount of Pt in one million cells was measured by ICP-MS.
In excellent agreement with the native protein electrophoresis
and CD results, complexes 1 and 4, which display weak aﬃnity
to BSA, are capable of entering the cell, showing high
accumulation rates (Figure 5). On the contrary, complexes 2
and 3 were unable to enter the cell, probably due to protein
sequestration in the media, which also explains their poor
cytotoxicity in all cell lines.
■ CONCLUSIONS
Four new platinum(II) analogue complexes (1−4) to cisplatin
have been synthesized and characterized, and their biological
properties have been studied. Investigations on new antitumor
Pt complexes have been focused since several decades ago on
ﬁnding similar behaviors to that of cisplatin. Interestingly, we
have veriﬁed that aquation is not a necessary step to bind
covalently to DNA. Moreover, although albumin proteins have
Figure 3. Native acrylamide electrophoresis of BSA incubated with
complexes 1−4 for 72 h for [complex]/[BSA] concentrations ratios of
10 and 20. CBSA = 1.5 μM, CDMSO = 0.3%.
Figure 4. CD spectra of BSA in the absence and in the presence of the
four platinum complexes 1−4 at a [complex]/[BSA] concentration
ratio of 5. CBSA = 0.5 μM, CDMSO = 0.002%, I = 2.5 mM sodium
cacodylate (NaCac), pH = 7.4, and T = 25 °C.
Figure 5. Metal accumulation in A549 cells after 24 h of exposure to
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been largely regarded as potential anticancer targets, we have
shown that the interaction with BSA correlates with poor cell
uptake of the platinum complexes, as occurs with complexes 2
and 3, which can interact covalently with DNA but are
prevented from reaching their target because of this strong
interaction. By contrast, complexes 1 and 4, which interact with
DNA by covalent and noncovalent binding, respectively, are
more cytotoxic, because they display weak eﬀect on BSA, and,
consequently, accumulation of the metal complex in tumor cells
increases, improving their antiproliferative eﬃcacy. In view that
1 and 2, on one hand, and 3 and 4, on the other hand, diﬀer
only by the lateral chain located on the same structural
backbone, we can conclude that the nature of these chains is
key to their remarkably diﬀerent behavior. In conclusion,
although the anticancer activity of cis-PtCl2 derivatives has been
linked to DNA interaction through covalent binding, we have
demonstrated that their antiproliferative capacity can be
diminished due to sequestration of the complexes by serum
albumin, which could be useful in the future design of more
potent platinum derivatives.
■ EXPERIMENTAL SECTION
Physical Methods. All synthetic manipulations were performed
under an inert, oxygen-free, dry nitrogen atmosphere using standard
Schlenk techniques. Solvents were distilled from the appropriate
drying agents and degassed before use. Elemental analyses were
performed with a Thermo Quest FlashEA 1112 microanalyser. The
analytical data for the new complexes were obtained from crystalline
samples where possible. IR spectra were recorded on a Shimadzu IR
Prestige-21 IR spectrophotometer equipped with a Pike Technologies
ATR. Only relevant bands are collected. FAB MS (position of the
peaks in Da) were recorded with an Autospec spectrometer or a
Thermo MAT95XP mass spectrometer with a magnetic sector. NMR
spectra were recorded at 298 K on a Varian Unity Inova 400 or on a
Varian Innova 500 spectrometer. 1H and 13C{1H} NMR chemical
shifts were internally referenced to tetramethylsilane (TMS) via the
residual 1H and 13C signals of CDCl3 (δ = 7.26 ppm and δ = 77.16
ppm), DMSO-d6 (δ = 2.50 ppm and δ = 39.52 ppm), and D2O (δ =
4.79 ppm) according to the values reported by Fulmer et al.45
Chemical shift values are reported in parts per million, and coupling
constants (J) are in hertz. The splitting of proton resonances is deﬁned
as s = singlet, d = doublet, t = triplet, q = quadruplet, m = multiplet, bs
= broad singlet. 2D NMR spectra were recorded using standard
pulse−pulse sequences: COrrelation SpectroscopY (COSY), Nuclear
Overhauser Enhancement SpectroscopY (NOESY), Heteronuclear
Multiple Quantum Coherence (HMQC), Heteronuclear Multiple
Bond Correlation (HMBC). The probe temperature (±1 K) was
controlled by a standard unit calibrated with a methanol reference. All
NMR data processing was performed using MestReNova version 6.1.1.
Materials. Unless otherwise stated, reagents and solvents used
were commercially available reagent quality. Conventional solvents
and K2CO3 were purchased from Scharlab. Deuterated solvents were
purchased from Eurisotop. K2[PtCl4] was purchased from Johnson
Matthey PLC. [PtCl2(PhCN)2]
46 and the ligands pbiCN25 and bpyst28
were prepared according to the literature. 4,4′-dicarboxy-2,2′-
bipyridine, 4,4′-dimethy-2,2′-bipyridine, 2-(2-pyridyl)benzimidazole,
acrylonitrile, 1,3-propanesultone, SOCl2, 2-amine-5-diethylaminopen-
tane, and trimethylamine were purchased from Across Organics.
The synthesized Pt(II) complexes can be referred to as dyes/drugs,
and their molar concentration is expressed as CD. Calf thymus DNA
(lyophilized sodium salt, highly polymerized) from Sigma-Aldrich was
dissolved in water and sonicated, producing short polynucleotide
fragments (ca. 1000 base pairs). The molar DNA concentration is
expressed in base pairs, ε (260 nm) = 13 200 M−1 cm−1.47 BSA was
supplied by Sigma-Aldrich as crystallized and lyophilized powder
(≥98%, agarose gel electrophoresis and ≤0.005% fatty acids); its
concentration was spectrophotometricaly determined at 278 nm using
absorptivity (ε) of 45 000 M−1 cm−1.48 Plasmid pUC18 (2686 bp) was
extracted from Escherichia coli DH5α and puriﬁed by a HP Plasmid
Midi kit (Omega Biotek, VWR). The concentrations of the polymers
(ctDNA, BSA, and pUC18) are denoted as CP.
Synthesis of Ligands and Complexes. 1-(Cyanoethyl)-2-(2-
pyridyl)benzimidazole (pbiCN). K2CO3 (318.6 mg, 2.3 mmol) was
added to a solution of 2-(2-pyridyl)benzimidazole (300 mg, 1.5 mmol)
in DMF (3 mL). The mixture was stirred at room temperature for 30
min. Then, 101 μL of acrylonitrile (1.5 mmol) was added, and the
reaction was stirred for 4 h. The solvent was removed by vacuum
evaporation resulting in a beige solid that was extracted with 10 × 3
mL of CHCl3. The organic extracts were combined, obtaining 289.2
mg of the pure product, beige colored, after drying under vacuum.
Yield, 76%.
3-(2-(2-pyridyl)-benzimidazol-1-yl)propane-1-sulfonate (pbiSO3).
A solution containing 318.6 mg of K2CO3 (2.3 mmol) was added over
another with 2-(2-pyridyl)benzimidazole (300 mg, 1.5 mmol) in DMF
(3 mL). The mixture was stirred at room temperature for 30 min.
Then, 135 μL of 1,3-propanesultone (1.5 mmol) was added, and the
mixture was stirred for 24 h. The mixture was ﬁltered, and the solvent
was removed by evaporation under vacuum. A yellow solid was
obtained. 265.3 mg, yield: 55%. 1H NMR (DMSO-d6, 298 K): 8.79 (d,
JHH = 4.7 Hz, 1H, H
6); 8.34 (d, JHH = 8 Hz, 1H, H
3); 8.05 (t, JHH = 8
Hz, 1H, H4); 7.82 (d, JHH = 7.2 Hz, 1H, H
3′); 7.76 (d, JHH = 7.7 Hz,
1H, H6′); 7.57 (m, 1H, H5); 7.40 (t, JHH = 7.7 Hz, 1H, H5′); 7.35 (t,
JHH = 7.7 Hz, 1H, H
4′); 4.97 (t, JHH = 7.2 Hz, 2H, Hγ); 2.43 (t, JHH =
7.8 Hz, 2H, Hα); 2.13 (m, 2H, Hβ) ppm. 1H NMR (D2O, 298 K): 8.61
(bs, 1H); 7.95 (t, JHH = 7.8 Hz, 1H); 7.84 (d, JHH = 7.4 Hz, 1H); 7.66
(d, JHH = 7.8 Hz, 1H); 7.60 (d, JHH = 7.8 Hz, 1H); 7.49 (t, JHH = 6 Hz,
1H); 7.35 (t, JHH = 7.4 Hz, 1H); 7.29 (t, JHH = 7.8 Hz, 1H); 4.57 (t,
JHH = 7.2 Hz, 2H); 2.58 (m, JHH = 7.2 Hz, 2H); 2.02 (q, JHH = 7.2 Hz,
2H) ppm. 13C{1H} NMR (DMSO-d6, 298 K): 149.2(C
6); 137.6(C4);
124.8(C5); 125.7(C3); 123.8(C5′); 123.2(C4′); 118.5(C6′); 111,7-
(C3′); 48.4(Cα); 44.4(Cγ); 26.3(Cβ) ppm. Elemental analysis (%):
Calculated (C15H14Cl2KN3 O3S·H2O): C, 48.32; H, 4.32; N, 11.25; S,
8.59. Found: C, 48.43; H, 4.38; N, 10.86; S, 8.69%. IR (ATR): ν(S
O) 1184, 1041 cm−1.
4,4′-bis(N-(4-pentyldiethylamine)carbamoyl)-2,2′-bipyridine
(bpyam). Ligand bpyam was synthesized in several steps in nitrogen
atmosphere. SOCl2 (3 mL) was added to 200.0 mg (0.8 mmol) of the
starting dicarboxylic bipyridine under inert atmosphere, and the
mixture was reﬂuxed overnight. The initial white suspension changed
to bright yellow solution during the reaction. Solvent was removed
under vacuum, and the resulting solid was used without further
puriﬁcation for the following step. 2-Amine-5-diethylaminopentane
(320.0 μL, 1.6 mmol) and 230.0 μL (1.6 mmol) of trimethylamine
were dissolved in 10 mL of dry dichloromethane, and on this solution
another of the acylchloride derivative in 10 mL of dry CH2Cl2 was
added drop by drop from a pressure equalizing dropping funnel. After
it was stirred overnight at room temperature, the solvent was
evaporated, obtaining a pink solid, which was washed with diethyl
ether four times (4 × 10 mL). In this operation, the remaining
chloride acid is removed from the solid mixture. This mixture contains
a big amount of NHEt3Cl, which can be removed using an aluminum
column of 10 cm long and 1 cm2 section. The mixture was eluted in 2
mL of MeOH and transferred to the column that was previously
wetted with CH2Cl2. The reaction product elutes with MeOH/CH2Cl2
(4/30 mL). The NHEt3Cl salt is retained in the column. A pinky-
white colored solid was obtained after complete evaporation of the
solvents. Yield: 93% (401.5 mg). Elemental analysis (%): Calculated
(C30H48N6O2): C, 68.67; H, 9.22; N, 16.02. Found: C, 68.36; H, 9.82;
N, 15.76. 1H NMR (DMSO-d6, 298 K), δ: 8.87 (d, 2H, J = 5.4 Hz,
H6), 8.80 (bd, 2H, J = 7.3 Hz, NH), 8.79 (s, 2H, H3), 7.89 (dd, 2H, J =
5.2, J = 1.7 Hz, H5), 4.10 (m, 2H, H4′), 2.42 (q, 8H, J = 7.4 Hz, H6′),
2,35 (t, 4H, J = 7.3 Hz, H1′), 1.50−1.56 (m, 4H, H3′), 1.40−1.44 (m,
4H, H2′), 1.21 (d, 6H, J = 6.9 Hz, H5′), 1.18 (t, 12H, J = 8.8 Hz, H7′)
ppm. 13C {1H} NMR (DMSO-d6, 298 K): 164.21 (CO), 155.49 (C
2),
149.97 (C6), 143.14 (C4), 122.11 (C5), 118.31 (C3), 50.46 (C1′),
46.64 (C6′), 44.70 (C4′), 32.83 (C3′), 20.62 (C2′), 20.25 (C5′), 8.53
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(C7′) ppm. FTIR (ATR): 3429 νNH, 1635 ν(CO) cm−1. MS-FAB+:
526 (100%, [M+2H]+) m/z.
[PtCl2(pbiCN)], 1. A solution containing 50 mg of pbiCN (0.2
mmol) in 9 mL of acetone was added to another with 83.6 mg of
K2[PtCl4] (0.2 mmol) in 4 mL of water. The mixture was stirred at 50
°C for 4 d. The yellow precipitate was ﬁltered and washed with water,
ethanol, and diethyl ether (3 mL each one). A yellow solid was
obtained. 55.9 mg, yield: 54%. Elemental analysis (%): Calculated
(C15H12Cl2N4Pt): C, 35.03; H, 2.35; N, 10.89. Found: C, 35.51; H,
1.91; N, 10.11. 1H NMR (DMSO-d6, 298 K): 9.66 (d, JHH = 6.5 Hz,
1H, H6); 9.01 (d, JHH = 8.3 Hz, 1H, H
6′); 8.42 (m, 2H, H3 and H4);
8.09 (d, JHH = 8.3 Hz, 1H, H
3′); 7.84 (t, JHH = 6.5 Hz, 1H, H5); 7.60
(t, JHH = 7.8 Hz, 1H, H
4′); 7.50 (t, JHH = 7.8 Hz, 1H, H5′); 5.20 (t, JHH
= 6.4 Hz, 2H, Hβ); 3.24 (t, JHH = 6.4 Hz, 2H, H
α) ppm. The
corresponding 13C{1H} NMR was not registered, because the complex
evolves in DMSO solution. MS-FAB+: 557 (M−Cl+DMSO) m/z. IR
(ATR): ν(CN) 2249 cm−1.
[PtCl2(pbiSO3)], 2. Over a solution containing 76.21 mg of pbiSO3
(0.24 mmol) in 5 mL of acetone, another of K2[PtCl4] (100 mg, 0.24
mmol) in 5 mL of water was added. The mixture was stirred at 50 °C
for 24 h. The solvent was removed by vacuum evaporation, leaving a
brown solid. 111 mg, yield: 74%. Elemental analysis (%): Calculated
(C15H14Cl2KN3O3PtS): C, 28.29; H, 2.27; N, 6.76; S, 5.26. Found: C,
28.21; H, 2.16; N, 6.82; S, 5.23. 1H NMR (DMSO-d6, 298 K): 9.63 (d,
J = 6.1 Hz, 1H, H6); 8.95 (d, J = 8.2 Hz, 1H, H6′); 8.70 (d, J = 7.9 Hz,
1H, H3); 8.32 (t, J = 7.9 Hz, 1H, H4); 8.03 (d, J = 8.2 Hz, 1H, H3′);
7.79 (t, J = 6.1 Hz, 1H, H5); 7.53 (t, J = 7.6 Hz, 1H, H4′); 7.43 (t, J =
7.6 Hz, 1H, H5′); 4.97 (t, J = 7.9 Hz, 2H, Hγ); 2.67 (t, J = 6.2 Hz, 2H,
Hα); 2.13 (m, 2H, Hβ) ppm. 13C{1H} NMR (DMSO-d6, 298 K):
150.54 (C6); 141.18 (C4); 128.07 (C5); 126.16 (C4′); 125.98 (C3);
125.74(C5′); 119.07 (C6′); 112.81 (C3′); 47.99 (Cα); 44.80 (Cγ);
25.87 (Cβ) ppm. MS-FAB−: 582 [M−K]− m/z. IR (ATR): ν(S0)
1184, 1043 cm−1.
[PtCl2(bpyam)], 3. The product was obtained by diﬀusion of the
reactants in phases. In a crystallization tube under inert atmosphere,
three phases were added: the lower phase consisted of a K2[PtCl4]
solution (15.8 mg, 0.04 mmol) in 2 mL of water; middle phase of 1
mL of water; the upper phase consisted of the ligand solution of (20.0
mg, 0.04 mmol) in 1 mL of water. Phases were allowed to fully diﬀuse.
The precipitate was ﬁltered and washed with water, aﬀording the
product as a yellow solid. Yield: 56% (17.7 mg). The product can be
obtained in a bigger amount by direct reaction in Schlenk, by stirring
overnight. Elemental analysis (%): Calculated (C30H48Cl2N6O2Pt): C:
45.57, H: 6.12, N: 10.63. Found: C: 45.31, H: 6.25, N: 10.42. 1H NMR
(DMSO-d6, 298 K), δ: 9.63 (d, 2H, J = 5.4, H
6), 9.60 (bs, 2H,
H3A or B), 9.46 (bs, 2H, H
3
A or B), 9.45(bs, 2H, -NHEt2), 9.16, (d, 2H, J
= 5.3, NHA or B), 9.13 (d, 2H, J = 5.3, NHA or B), 8.23 (m, 2H, H
5),
4.14 (m, 2H, H4′), 2.92 (m, 12H, H1′ + H6′), 1.55−1.80 (m, 8H, H2′
+ H3′), 1.27 (d, 6H, J = 6.3 Hz, H5′), 1.13 (bs, 12H, H7′) ppm.
13C{1H} NMR (DMSO-d6, 298 K): 161.60 (COA or B), 161.52
(COA or B), 157.27 (C
2
A or B), 157.23 (C
2
A or B), 148.96 (C
6), 143.77
(C4A or B), 143.65 (C
4
A or B), 126.12 (C
5), 121.74 (C3A or B), 121.68
(C3A or B), 50.71 (C
1′), 46.10 (C6′), 45.48 (C4′A or B), 45.42 (C4′A or B),
32.73 (C3′), 20.59 (C5′), 20.56 (C2′), 9.14 (C7′) ppm. A and B stands
for the two diastereomers (if not indicated, the resonance signal for
both diastereomers is the same). Fourier transform infrared attenuated
total reﬂectance (FTIR ATR): 3432 ν(NH), 1637 ν(CO) cm−1.
MS-FAB+: 792 (15%, [M+2H]+); 756 (7%, [M−Cl + H]+); 526
(100%, [L+2H]+) m/z.
[PtCl2(bpyst)], 4. Ligand of this complex ((4,4′-bis(α-styrene)-2,2′-
bipyridine (bpyst)) was prepared as previously reported.28 A yellow
colored solution of [PtCl2(NCPh)2] was prepared in 40 mL of
dichloroethane (106.7 mg, 0.226 mmol). Over this solution another
solution of the ligand bpyst was added (82 mg, 0.226 mmol). The
suspension was maintained for 2 d at 60 °C. The formation of a yellow
precipitate was observed, and the solution turned to yellow-brown.
The precipitate was ﬁltered, and the solution was evaporated to 3 mL.
Diethyl ether was added to complete precipitation of a solid. The
solution was sonicated for 5 min and ﬁltered out in a porous glass
ﬁlter. The obtained brown solid was washed with diethyl ether (3 × 3
mL) and dried under vacuum. Yield: 65% (92.3 mg). Elemental
analysis (%): Calculated (C26H22Cl2N2Pt): C: 49.69, H: 3.53, N: 4.46.
Found: C: 49.51, H: 3.64, N: 4.37. 1H NMR (DMSO-d6, 298 K), δ:
9.40 (d, 2H, JHH = 6.2 Hz, H
6); 8.85 (s, 2H, H3); 7.99 (d, 2H, JHH =
16.5 Hz, Holef), 7.94 (d, 2H, JHH = 6.2 Hz, H
5); 7.77 (d, 4H, JHH = 7.8
Hz, H°); 7.53−7.45 (m, 8H, Hm, Hp, and Holef) ppm. The
corresponding 13C{1H} NMR resonances are not indicated, because
the signals are too broad for a proper assignment. FTIR (ATR): 1612
(ν(CC) cm−1. MS-FAB+: 591 (4%, M−Cl−2H) m/z.
General Procedure of Stability and Binding to dGMP by
NMR Studies. Stability in DMSO-d6. Complexes 1−4 (5−8 mg) were
dissolved in 0.5 mL of DMSO-d6, and
1H NMR spectra were recorded
during 7 d in a 400 MHz spectrometer.
Aquation Studies. Over the previous solution, 50 μL of D2O was
added, and 1H NMR spectra were recorded during 7 d in a 400 MHz
spectrometer.
Binding Studies to dGMP. Over the solution coming from the
aquation studies, 5 mg of dGMP dissolved in 20 μL of D2O was added,
and 1H NMR and 31P{1H} spectra were recorded during 5 d in a 400
MHz spectrometer.
UV−Vis Spectroscopy. Absorbance measurements were per-
formed to study the substitution of the chloro ligands of the metal
complexes for DMSO and H2O molecules when NMR experiments
were not suitable because of precipitation phenomena. Measurements
were performed on a Hewlett-Packard 8453A (Agilent Technologies)
photodiode array spectrophotometer ﬁtted out with a Peltier
temperature control system at T = 25 °C in 1.0 cm path-length cells.
Circular Dichroism. CD studies were performed by incubating
ctDNA or BSA with the metal complexes for 72 h, in sodium
cacodylate (NaCac) buﬀer (I = 2.5 mM) at pH = 7.4 and T = 25 °C
and recording the CD spectra with a MOS-450 biological
spectrophotometer (Bio-Logic SAS) in 1.0 cm path-length cells. As
DMSO can aﬀect the CD spectra of the biomolecules, the control
measurements (ctDNA or BSA in the absence of metal complex) were
incubated with the same DMSO percentage as the samples under the
same experimental condition.
Diﬀerential Scanning Calorimetry. To prepare the DSC
samples, ctDNA (4 × 10−4 M) was incubated with the metal
complexes for 72 h, in NaCac buﬀer (I = 2.5 mM) at pH = 7.4 and T =
25 °C. For the control measurement, ctDNA in the absence of metal
complex was incubated with the same DMSO content as the other
samples under the same experimental conditions. Before recording the
DSC measurements, the samples were degassed for 30 min in a
degassing station (TA Instruments). DSC thermal denaturation
studies were performed with a nano DSC (TA Instruments) by
scanning at 3 atm pressure from 25 to 95 °C at 1 °C·min−1 scan rate.
The DCS curves were analyzed using the NanoAnalyze (TA
Instruments) software.
Viscosity Measurements. Viscosity measurements were per-
formed with an Ubbelohde viscometer (Schott) immersed in a water
bath at T = 25 °C. The ﬂow time was measured with a digital
stopwatch. The sample viscosity was evaluated as the mean value of at
least four replicated measurements. The viscosity readings were
reported as L/L0 = (η/η0)
1/3 versus CD/CP ratio, where η and η0 stand
for the polynucleotide viscosity in the presence and in the absence of
the metal complex, respectively.
Cytotoxic Activity. 2.5 × 103 HeLa (human cervical carcinoma)
or A549 (human lung carcinoma) cells were seeded in 200 μL culture
medium per well (DMEM medium), supplemented with 10% FBS and
1% amphotericin-penicillin-streptomycin solution in 96-well plates and
incubated in a humid atmosphere at 37 °C under 5% CO2 atmosphere
for 24 h. Cells were then incubated for 72 h with 100 μL of culture
medium (supplemented either with 10% or 1% of FBS) with diﬀerent
concentrations of the metal complexes in culture medium. Cisplatin
was also included as a positive control. Then, 100 μL of 500 μg/mL of
MTT (thiazolyl blue tetrazolium bromide) was added to each well and
incubated for 4 h. Lastly, the formazan product was dissolved by
adding 100 μL of solubilizing solution (10% sodium dodecyl sulfate
(SDS) in 0.01 M HCl) and allowing the solution to solubilize
overnight. Absorbance was read at 590 nm in a microplate reader
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(Biotek Instruments). Four replicates per dose were included in each
experiment, and half-maximal inhibitory concentration (IC50) values
were calculated using the GraphPad Prism 6.01 analysis software
(GraphPad Software Inc.) from three independent experiments.
Native Protein Electrophoresis. Native polyacrylamide gel
electrophoresis (PAGE) was performed by incubating BSA overnight
with diﬀerent concentrations of the platinum complexes for
[complex]/[protein] concentration ratios of 10 and 20 in Tris HCl
buﬀer (0.5 M, pH = 6.8) and T = 25 °C. After that, 5 μL of sample
buﬀer 2X (0.01% bromophenol blue and 20% glycerol in Tris HCl
buﬀer (0.5 M, pH 6.8) were added to 5 μL of the sample solutions and
loaded onto 10% polyacrylamide gels. Gels were run in tris borate and
EDTA (TBE) ×1 buﬀer at 80 V for 4 h at 4 °C to avoid denaturation
of the protein. Finally, gels were stained with Coomassie Brilliant Blue
R-250 and visualized with a Gel Doc XR+ Imaging System (Bio-Rad).
Agarose Gel Electrophoresis. Agarose gel electrophoresis of
plasmid DNA (pUC18) was performed after incubation of the plasmid
(15 μM, base pairs) in the presence of diﬀerent concentrations of
complex 4 (1.5−750 μM) or cisplatin (15 and 150 μM) for 72 h. A
vehicle-treated pUC18 sample was included with the maximum
DMSO concentration used in the electrophoresis experiment. Loading
buﬀer (2 μL) was added to each sample (10 μL) prior to being loaded
onto a 1% agarose gel containing 0.05 μg mL−1 ethidium bromide.
Electrophoresis was run at 5 V/cm for 2 h in TBE ×1 buﬀer, and the
gel was visualized with a Gel Doc XR+ Imaging System (Bio-Rad).
Cellular Uptake Studies. A549 cells were seeded in culture ﬂasks
(2.5 × 106 cells in 6 mL DMEM culture medium and incubated for 24
h at 37 °C and 5% CO2. After that, cells were treated with the
indicated concentrations of the Pt complexes for 24 h and harvested in
phosphate buﬀered saline. The samples were digested with 65% HNO3
at room temperature for 24 h and then diluted with Milli-Q water to
obtain 2% HNO3 solutions to be analyzed by inductively coupled
plasma-mass spectrometry (ICP-MS).
Computational Details. The geometries of reactants, intermedi-
ates, products, and transition states were fully optimized by DFT
calculations, using the B3LYP,49 PBE0,50 and M06-2X51 functionals,
the CEP-121G52 eﬀective potential basis set for the Pt atom, and the
6-31G(d,p)53 basis set for the other atoms, as recently reported.54,55
Water solvent eﬀects were mimicked by the “conductor-like polarized
continuum model” implicit method.56 The reaction pathway leading to
hydrolysis of 4 was followed by a two-step nucleophilic substitution
mechanism, widely accepted and reported in the literature.57 The
geometry of the transition states was optimized by the synchronous
transit quasi-Newton method.58 Vibrational analysis, in the harmonic
approximation, was performed. This allowed us to evaluate also the
enthalpy and the Gibbs free energy diﬀerences along the reaction
pathways. Energy minimum structures presented no imaginary
frequencies, while all transition states were ﬁrst-order saddle points
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